申请人:SMITHKLINE BECKMAN CORPORATION
公开号:EP0302603A1
公开(公告)日:1989-02-08
Compounds of formula (I):
in which X is H, F, Cl, Br, C₁₋₄alkyl, CN, NO₂, SO₂NH₂, COOH, OH, CHO, C₁₋₄alkoxy, CH₂OH, CH₂OC₁₋₄alkyl, CF₃, C₂F₅, C₃F₇, SO₂CH₃, SO₂CF₃, or CO₂CaH2a+1 wherein a is 1-5, or any accessible combination thereof of up to 5 substituents; R is H or C₁₋₄alkyl; and n is 0-5; and salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy as inhibitors of dopamine-β-hydroxylase activity.
式 (I) 的化合物:
其中 X 是 H、F、Cl、Br、C₁₋₄alkyl、CN、NO₂、SO₂NH₂、COOH、OH、CHO、C₁₋₄alkoxy、CH₂OH、CH₂OC₁₋₄alkyl、CF₃、C₂F₅、C₃F₇、SO₂CH₃、SO₂CF₃、或 CO₂CaH2a+1,其中 a 为 1-5 个取代基,或最多 5 个取代基的任何可获得的组合;R是H或C₁₋₄烷基;n是0-5;以及它们的盐、它们的制备工艺、含有它们的药物组合物和它们在治疗中作为多巴胺-β-羟化酶活性抑制剂的用途。